Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poliovirus capsid D antigen (also known as the native or N-antigen) is the conformationally native, infectious form of the poliovirus protein capsid. The capsid is an icosahedral structure composed of 60 copies of four viral structural proteins: VP1, VP2, VP3, and VP4. The D-antigen is the critical immunogenic component of inactivated polio vaccines (IPV), as it is the primary form capable of inducing the production of protective neutralizing antibodies in the host. In contrast, the non-infectious, empty, or heated capsid form is known as the C-antigen (or H-antigen), which lacks genomic RNA and does not elicit a protective neutralizing immune response. Quantification of D-antigen units (D-AgU) is the standard method for determining the potency and stability of IPV formulations during manufacturing. Vaccines targeting this antigen, such as IPOL and various combination vaccines (e.g., Pentacel, Vaxelis), have been highly successful in the global effort to eradicate poliomyelitis.
Active immunization by inducing neutralizing antibodies against poliovirus serotypes 1, 2, and 3
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus capsid D antigen (D-Ag).